O-2545
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (6aR,10aR)-6a,7,10,10a-Tetrahydro-3-[5-(1H-imidazol-1-yl)-1,1-dimethylpentyl]-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Unscheduled |
| Identifiers | |
| CAS number | 874745-42-3  |
| ATC code | ? |
| Chemical data | |
| Formula | C26H36N2O2 |
| Mol. mass | 408.575 g/mol |
| SMILES | eMolecules & PubChem |
 (what is this?) (verify) |
O-2545 is an analgesic cannabinoid derivative created by Organix Inc. for use in scientific research. Unlike most cannabinoids discovered to date, it is water soluble, which gives it considerable advantages over many related cannabinoids. It has high affinity for both CB1 and CB2 receptors, with Ki values of 1.5nM at CB1 and 0.32nM at CB2.[1]
[edit] See also
[edit] References
- ^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK. Pharmacological characterization of novel water-soluble cannabinoids. Journal of Pharmacology and Experimental Therapeutics. 2006 Sep;318(3):1230-9. PMID 16757541
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
